Condition Directory

Non-Small Cell Lung Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Non-Small Cell Lung Cancer. Browse Non-Small Cell Lung Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 1, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3693

Shown on this page

Current sort

How Non-Small Cell Lung Cancer studies are organized in the registry

NSCLC is one of the most biomarker-organized portfolios in the registry: EGFR, ALK, ROS1, KRAS G12C, and PD-L1 status define many study populations and appear verbatim in titles. Stage language also matters — stage III (often around chemoradiation) and stage IV/metastatic studies are designed differently and labeled accordingly.

Terms that often appear in related listings

EGFR ALK KRAS G12C stage III PD-L1

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 397–408 of 3,693 matching trials for Non-Small Cell Lung Cancer.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3
Interventions: Obrixtamig - parenteral 1, Obrixtamig - parenteral 2; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 4
States / cities: Atlanta, Georgia • Baltimore, Maryland • St Louis, Missouri + 1 more

Conditions: Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Berzosertib, Biospecimen Collection, Carboplatin, Computed Tomography, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Pembrolizumab; Drug · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 34
States / cities: Los Angeles, California • Newport Beach, California • Aventura, Florida + 25 more

Conditions: Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Ceralasertib, Computed Tomography, Durvalumab, Echocardiography Test; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 192
States / cities: Jonesboro, Arkansas • Beverly Hills, California • Los Angeles, California + 163 more

Conditions: Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
Interventions: BLU-924; Drug
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 10
States / cities: Sarasota, Florida • Tampa, Florida • Baton Rouge, Louisiana + 7 more

Conditions: Non Small Cell Lung Cancer Metastatic
Interventions: Acasunlimab, Pembrolizumab; Biological
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 6
States / cities: Santa Rosa, California • Fort Myers, Florida • St. Petersburg, Florida + 3 more

Conditions: Non Small Cell Lung Cancer, ALK-positive Non-small Cell Lung Cancer (NSCLC)
Interventions: NVL-655; Drug
Lead sponsor: Nuvalent Inc.; Industry
Eligibility: 18 Years and older
U.S. locations: 13
States / cities: Orange, California • Aurora, Colorado • Chicago, Illinois + 8 more

Conditions: Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Osimertinib, Radiation Therapy, Therapeutic Conventional Surgery; Drug · Radiation · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 4
States / cities: San Francisco, California • Denver, Colorado • New York, New York + 1 more

Conditions: Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal
Interventions: Pembrolizumab Injection; Drug
Lead sponsor: Persephone Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 2
States / cities: Fountain Valley, California • Winter Haven, Florida

Conditions: Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Interventions: AU-007, Aldesleukin, Avelumab, Nivolumab; Drug
Lead sponsor: Aulos Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 7 more

Conditions: Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Ipilimumab, Local Consolidation Therapy, Nivolumab, Quality-of-Life Assessment, Radiation Therapy, Therapeutic Conventional Surgery; Biological · Procedure · Other + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 5
States / cities: Conroe, Texas • Houston, Texas • League City, Texas + 1 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Ivonescimab Injection, Pembrolizumab Injection; Biological
Lead sponsor: Summit Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 97
States / cities: Chandler, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 86 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: BMS-986504, Izalontamab Brengitecan; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 10
States / cities: Anchorage, Alaska • Boston, Massachusetts • Detroit, Michigan + 6 more

About this Non-Small Cell Lung Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Non-Small Cell Lung Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Non-Small Cell Lung Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Non-Small Cell Lung Cancer clinical trials

How Non-Small Cell Lung Cancer studies are organized in the registry

Filter and sort this condition

Live official records

A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors

Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study

Development and Analysis of a Stool Bank for Cancer Patients

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

About this Non-Small Cell Lung Cancer clinical trials directory page